Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Mohammad Peikari"'
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Abstract Completely labeled pathology datasets are often challenging and time-consuming to obtain. Semi-supervised learning (SSL) methods are able to learn from fewer labeled data points with the help of a large number of unlabeled data points. In th
Externí odkaz:
https://doaj.org/article/792b44f9bc9942699642a822cd3b0d25
Autor:
Robert P. Nolan, Mohammad Peikari, Chun-Po Steve Fan, Gabriel C. Fezza, Heather Joan Ross, Chris McIntosh
Publikováno v:
Journal of the American College of Cardiology. 79:2044
Publikováno v:
Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization. 7:260-265
Digital pathology has advanced substantially over the last decade with the adoption of slide scanners in pathology labs. The use of digital slides to analyse diseases at the microscopic level is both cost-effective and efficient. Identifying complex
Publikováno v:
Cytometry Part A. 91:1078-1087
Neoadjuvant treatment (NAT) of breast cancer (BCa) is an option for patients with the locally advanced disease. It has been compared with standard adjuvant therapy with the aim of improving prognosis and surgical outcome. Moreover, the response of th
Autor:
Sherine Salama, Anne L. Martel, Shazia Akbar, Mohammad Peikari, Sharon Nofech-Mozes, Azadeh Yazdan Panah
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
AimsThe residual cancer burden index is an important quantitative measure used for assessing treatment response following neoadjuvant therapy for breast cancer. It has shown to be predictive of overall survival and is composed of two key metrics: qua
Autor:
Brigitte Mueller, Heather J. Ross, Chun-Po Steve Fan, Karim Taha, Cedric Manlhiot, Edgar Crowdy, Mohammad Peikari
Publikováno v:
Journal of the American College of Cardiology. 75:2046
heart failure (HF) and coronary artery disease (CAD) have multi-faceted genetic, lifestyle and environmental contributors. Our capacity to predict their onset, and alter its course before serious morbidity, is limited by generic and weakly predictive
Publikováno v:
Medical Imaging: Digital Pathology
The residual cancer burden index is a powerful prognostic factor which is used to measure neoadjuvant therapy response in invasive breast cancers. Tumor cellularity is one component of the residual cancer burden index and is currently measured manual
Autor:
Ali Ghodsi, Anne L. Martel, Mehrdad J. Gangeh, Sharon Nofech-Mozes, Mohammad Peikari, Sherine Salama, Rene Bidart
Publikováno v:
Medical Imaging: Digital Pathology
Neoadjuvant therapy (NAT) is an option for locally advanced breast cancer patients to downsize tumour allowing for less extensive surgical operation, better cosmetic outcomes, and lesser post-operative complications. The quality of NAT is assessed by
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-13 (2018)
Completely labeled pathology datasets are often challenging and time-consuming to obtain. Semi-supervised learning (SSL) methods are able to learn from fewer labeled data points with the help of a large number of unlabeled data points. In this paper,
Publikováno v:
Cytometry. Part A : the journal of the International Society for Analytical Cytology. 91(11)
Neoadjuvant treatment (NAT) of breast cancer (BCa) is an option for patients with the locally advanced disease. It has been compared with standard adjuvant therapy with the aim of improving prognosis and surgical outcome. Moreover, the response of th